巴伐利亚皮肤科诊所中符合指南的生物制剂处方及可能障碍
该横断面问卷研究纳入巴伐利亚全部私人执业皮肤科医生,分析银屑病和慢性自发性荨麻疹生物制剂处方是否符合德国指南并评估处方障碍。2017年1月至2月共137名(499名中)皮肤科医生参与,报告中度至重度银屑病和慢性自发性荨麻疹患者中分别有14.2%和6.9%使用生物制剂,最常见障碍为治疗费用高、报销低和担心追索。
要点
- 参与医生报告中度至重度银屑病患者中14.2%使用生物制剂,慢性自发性荨麻疹患者中6.9%使用生物制剂。
- 最常见的处方障碍为治疗费用高、报销低和担心追索。
- 年龄、在皮肤科医院工作年数及治疗中度至重度银屑病患者数量影响对多种障碍的感知。
核心结论
- 需强调临床教育的作用以及外部和经济障碍相对于医疗障碍的重要性,生物制剂的指南符合性使用有待优化。
- 需要进一步研究以确定不仅适用于巴伐利亚而且适用于更广泛环境的障碍模式。
- 基于此针对银屑病需采取行动以实现世界卫生组织全球银屑病报告的目标,即加强以患者为中心的照护作用并改善受影响患者的生活质量,类似地这也适用于荨麻疹。
研究设计与样本
- 横断面问卷研究,纳入巴伐利亚所有私人执业皮肤科医生,使用线性回归和逻辑回归模型识别影响障碍感知的显著因素。
- 2017年1月至2017年2月期间,499名皮肤科医生中共137名参与。
主要发现
- 参与皮肤科医生报告,在所有中度至重度银屑病患者中14.2%使用生物制剂治疗,在所有慢性自发性荨麻疹患者中6.9%使用生物制剂治疗。
- 最常见的处方障碍为治疗费用高、报销低和担心追索。
- 分析显示年龄、在皮肤科医院工作年数及治疗中度至重度银屑病患者数量影响对许多障碍的感知。
- 年龄以及与医生因素和外部因素相关的障碍被确定为皮肤科医生处方模式的修饰因素。
关键数值与推荐
- 根据各自的德国指南,生物制剂可用于治疗这些疾病的严重形式。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以确定不仅适用于巴伐利亚而且适用于更广泛环境的障碍模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Psoriasis and urticaria are chronic inflammatory skin diseases, which account for a substantial socioeconomic burden and severely affect patients' quality of life. According to the respective German guidelines, biologicals can be used for the treatment of severe forms of these diseases. However, only a minority of patients receive this advised treatment. OBJECTIVE: To analyse the prescription of biologicals according to the German national guidelines for psoriasis and chronic spontaneous urticaria and to assess possible barriers to prescription. MATERIALS AND METHODS: Cross-sectional, questionnaire-based study including all Bavarian dermatologists based in private practices. Linear and logistic regression models were used to identify significant influencing factors on the perception of possible barriers. RESULTS: Between January 2017 and February 2017, a total of 137 (of 499) dermatologists participated. Of all patients with moderate to severe psoriasis and chronic spontaneous urticaria, participating dermatologists indicated treating 14.2% and 6.9% with biologicals, respectively. The most prevalent barriers to prescription were the high cost of the therapy, the low reimbursement and the fear of recourse. Analysis showed that age, years spent working in a dermatological hospital and the number of patients treated with moderate to severe psoriasis affect the perception of many barriers. Furthermore, age and barriers related to physician factors and external factors were identified as modifiers to the prescription scheme of dermatologists. CONCLUSIONS: The role of clinical education and the importance of external and economic barriers in comparison with medical barriers have to be emphasised. Guideline-compliant use of biologicals has to be optimised. Further research is needed to ascertain not only a barrier pattern for Bavaria but also for wider settings. Actions based on this for psoriasis are needed to achieve the goal of the WHO Global Psoriasis Report to strengthen the role of patient-centred care and improve the quality of life of affected patients. Analogue, this applies also for urticaria.
引用
- Schielein MC, Tizek L, Rotter M, et al. Guideline-compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria. J Eur Acad Dermatol Venereol. 2018. PMID: 29356181. doi:10.1111/jdv.14811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。